What is AKTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AKTX?

P/E (TTM) is n/a and 52-week range is $3.02 to $44.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AKTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AKTX?

The company profile lists net income (TTM) near $-8K, EPS (TTM) near $-0.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Akari Therapeutics PLC based, and what identifiers does Chartloom list?

The company context section lists headquarters in Tampa, Florida, US, 1.9M shares outstanding, ISIN US00972G4055 when available from company profile and filing metadata.

Akari Therapeutics PLC

$AKTX

Health Care · Biotechnology

IR Run Scenarios

$8.77

+7.87%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Tampa, Florida and currently employs 5 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Employees

Website

www.akaritx.com/

IPO

2014-01-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)